From 2,000+ patients · Semaglutide vs Tirzepatide is already seeing results
Semaglutide vs Tirzepatide: both are FDA-approved GLP-1 medications for weight loss. Semaglutide (semaglutide) and Tirzepatide (tirzepatide) differ in mechanism and clinical efficacy. Weight Method offers both from $199/month with virtual consultations and licensed providers.
Overview
Semaglutide and tirzepatide are two distinct molecules in the incretin-based medication class. Semaglutide was developed by Novo Nordisk and acts exclusively on the GLP-1 receptor. Tirzepatide was developed by Eli Lilly and is a dual GIP/GLP-1 receptor agonist, targeting two incretin pathways simultaneously. The branded, FDA-approved versions of these molecules are made by their respective manufacturers; Weight Method does not dispense or prescribe those brand-name products. Our program provides compounded semaglutide and compounded tirzepatide through licensed providers and U.S.-licensed pharmacies. Which molecule is appropriate for you is a decision made by a licensed provider based on your individual medical profile.
Key Fact
Semaglutide is a single-receptor GLP-1 agonist developed by Novo Nordisk. Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. They are two distinct molecules in the incretin-based class. The branded FDA-approved versions are different from Weight Method's compounded program. Both compounded options are available from $99/mo through Weight Method.
Source: FDA prescribing information; published mechanism-of-action literature
Semaglutide
Tirzepatide
| Semaglutide | Tirzepatide | |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Active Ingredient | semaglutide | tirzepatide |
| FDA Indication | Chronic weight management (Wegovy) / Type 2 diabetes (Ozempic) | Chronic weight management (Zepbound) / Type 2 diabetes (Mounjaro) |
| FDA Approval | 2021 | 2023 |
| Formulation | Injectable pen / Oral tablet | Injectable pen |
| Frequency | Once weekly (injectable) / Once daily (oral) | Once weekly |
| Available Doses | 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg |
| Avg. Weight Loss | 14.9% | 22.5% |
| Our Price | $199/mo | $329/mo |
Key Differences
The core distinction is mechanism of action: semaglutide is a single-receptor GLP-1 agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist. Semaglutide has been in clinical use longer and is available in both injectable and oral formulations; tirzepatide is newer and currently injectable only. Side effect profiles are similar — nausea, diarrhea, and vomiting are the most common with both. Which molecule is clinically appropriate for any individual depends on that person's BMI, medical history, and treatment goals and is determined by a licensed provider, not by a general comparison. Through Weight Method, both compounded medications start at $99/mo with licensed provider oversight.
Verdict
Semaglutide and tirzepatide are two distinct molecules with different mechanisms; the branded FDA-approved versions are not what Weight Method dispenses. The right option for an individual — and whether either is appropriate — depends on that person's BMI, medical history, and treatment goals and is determined by a licensed provider. Through Weight Method, both compounded options are available from $99/mo with licensed provider oversight.
Your Treatment Options
Compounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.
